title: Tenofovir-emtricitabine-efavirenz in HIV-I-infected adults in Senegal: a 96-week pilot trial in treatment-naive patients.
abstract: We report the results of a pilot open-label trial of a tenofovir (TDF)/emtricitabine (FTC)/efavirenz (EFV) combination conducted in Dakar, Senegal. Forty HIV-1-infected patients, naive of antiretroviral treatment and without active opportunistic disease, were included and followed through 96 weeks. At weeks 48 and 96, respectively, 82.5% and 85% of patients had HIV-1 RNA <400 copies/mL (72.5% and 77.5% with HIV-1 RNA <50 copies/mL). Between baseline and week 96, the mean (SD) CD4 count increased from 126 (102) to 338 (155) cells/mm(3). The mean (SD) creatinine clearance decreased from 92 (36) to 73 (19) mL/min (P = .001). Treatment adherence was at least 94% at all scheduled visits. The efficacy and tolerability of a TDF/FTC/EFV combination were high and similar to those observed in Northern countries. This drug combination can be recommended in limited-resource countries, as did the World Health Organization (WHO) and should be made readily available as a fixed-dose combination.
authors.affiliation: Institut de Médecine et d'Epidémiologie Appliquée et Hôpital Bichat-Claude Bernard, Service des Maladies Infectieuses, Paris, France. roland.landman@univ-paris-diderot.fr
authors.forename: Roland
authors.initials: R
authors.lastname: Landman
authors.forename: M
authors.initials: M
authors.lastname: Poupard
authors.forename: M
authors.initials: M
authors.lastname: Diallo
authors.forename: N F
authors.initials: NF
authors.lastname: Ngom Gueye
authors.forename: N
authors.initials: N
authors.lastname: Diakhate
authors.forename: B
authors.initials: B
authors.lastname: Ndiaye
authors.forename: C
authors.initials: C
authors.lastname: Toure Kane
authors.forename: A
authors.initials: A
authors.lastname: Trylesinski
authors.forename: H
authors.initials: H
authors.lastname: Diop
authors.forename: S
authors.initials: S
authors.lastname: Mboup
authors.forename: M B
authors.initials: MB
authors.lastname: Koita Fall
authors.forename: E
authors.initials: E
authors.lastname: Delaporte
authors.forename: A
authors.initials: A
authors.lastname: Benalycherif
authors.forename: P M
authors.initials: PM
authors.lastname: Girard
authors.forename: P S
authors.initials: PS
authors.lastname: Sow
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D048588:Benzoxazines / Q000494:pharmacology / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D003521:Cyclopropanes; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000068679:Emtricitabine; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000523:psychology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D063065:Organophosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D010865:Pilot Projects; D011788:Quality of Life; D012367:RNA, Viral / Q000097:blood; D012675:Senegal; D000068698:Tenofovir
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D063065:Organophosphonates; D012367:RNA, Viral; D003841:Deoxycytidine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine; C098320:efavirenz